An experimental gene-editing therapy for hereditary angioedema (HAE), called NTLA-2002, has been administered to the first participant in the Phase 2 portion of a clinical trial, according to its developer, Intellia Therapeutics. “We are pleased to announce dosing has begun in the Phase 2 study of NTLA-2002,”…

Donidalorsen significantly reduced swelling attacks and improved quality of life in people with hereditary angioedema (HAE) treated in a Phase 2 trial. Full trial results were detailed in the study, “Inhibition of Prekallikrein for Hereditary Angioedema,” published in The New England Journal of Medicine. The study…

Single, on-demand treatment with the investigational oral medicine KVD900 safely and significantly slowed the progression of swelling attacks and shortened the time to symptom relief and resolution in adults with hereditary angioedema (HAE), according to the latest data from a Phase 2 trial. “HAE patients continue to seek…

KVD900, an oral experimental on-demand treatment for swelling episodes caused by hereditary angioedema (HAE), safely and significantly reduced the severity of attacks and shorted the time to improvement, which was maintained for 24 hours, according to Phase 2 trial data.  “Our goal is to provide the best outcome…

The experimental therapy IONIS-PKK-LRx can significantly lower the number of monthly swelling attacks in patients with hereditary angioedema (HAE) type 1 and 2, according to top-line data from an ongoing Phase 2 trial. Newly announced data show the study (NCT04030598), sponsored by therapy developer Ionis Pharmaceuticals,…

KVD001 safely protects people with diabetic macular edema from losing their vision, according to a Phase 2 trial conducted by the treatment’s developer, KalVista Pharmaceuticals. DME is a form of angioedema that is caused by the leaking of blood vessels which lead to fluid accumulating in the…

KalVista Pharmaceuticals’ investigational candidate KVD900, being developed for the treatment of hereditary angioedema (HAE), is safe and effectively inhibits kallikrein, the main driver of HAE attacks, results from a Phase 1 clinical trial show. Following these positive results, the company is now launching a larger Phase 2…